Douglas R Sidell, Karthik Balakrishnan, Simon R Best, Karen Zur, Julia Buckingham, Alessandro De Alarcon, Fuad M Baroody, Jonathan M Bock, Emily F Boss, Charles M Bower, Paolo Campisi, Sharon F Chen, Jeffrey M Clarke, Kevin D Clarke, Alejandro Cocciaglia, Robin T Cotton, Giselle Cuestas, Kara L Davis, Victor H DeFago, Frederik G Dikkers, Ines Dossans, Walter Florez, Elizabeth Fox, Aaron D Friedman, Nazaneen Grant, Osama Hamdi, Norman D Hogikyan, Kaalan Johnson, Liane B Johnson, Romaine F Johnson, Peggy Kelly, Adam M Klein, Claire M Lawlor, Nicolas Leboulanger, Alejandro G Levy, Derek Lam, Greg R Licameli, Steve Long, David G Lott, Dayse Manrique, James Scott McMurray, Kara D Meister, Anna H Messner, Michael Mohr, Pamela Mudd, Anthony J Mortelliti, Daniel Novakovic, Julian Ongkasuwan, Shazia Peer, Krysztof Piersiala, Jeremy D Prager, Seth M Pransky, Diego Preciado, Tiffany Raynor, Rico N P M Rinkel, Hugo Rodriguez, Verónica P Rodríguez, John Russell, María Laura Scatolini, Patrick Scheffler, David F Smith, Lee P Smith, Marshall E Smith, Richard J H Smith, Abraham Sorom, Amalia Steinberg, John A Stith, Dana Thompson, Jerome W Thompson, Patricio Varela, David R White, Andre M Wineland, Christina J Yang, Carlton J Zdanski, Craig S Derkay
OBJECTIVES/HYPOTHESIS: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. STUDY DESIGN: Delphi method-based survey series. METHODS: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established...
January 6, 2021: Laryngoscope